VRON 0300
Alternative Names: VRON-0300Latest Information Update: 17 Nov 2023
At a glance
- Originator Ocean Biomedical - Virion Therapeutics (JV); Virion Therapeutics
- Class Cancer vaccines; Immunotherapies
- Mechanism of Action Checkpoint kinase modulators; Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Nov 2023 Ocean Biomedical announces intention to submit IND for Solid tumours within the next 9 months
- 20 Oct 2023 Virion Therapeutics plans a phase Ib trial for Solid tumours (Late-stage disease) in Q2 2024 (Virion Therapeutics pipeline, October 2023)
- 19 Oct 2023 Preclinical trials in Solid tumours in USA (Parenteral) (Virion Therapeutics pipeline, October 2023)